TrialCancer cell2019

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jacqulyne P Robichaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.